| ID Source | ID |
|---|---|
| PubMed CID | 87935 |
| CHEMBL ID | 1472131 |
| SCHEMBL ID | 372370 |
| MeSH ID | M0526689 |
| Synonym |
|---|
| SR-01000636460-1 |
| MLS000780025 , |
| 2-butyl-6-butylamino-benzo[de]isoquinoline-1,3-dione |
| smr000420208 |
| 2-butyl-6-(butylamino)-1h-benz(de)isoquinoline-1,3(2h)-dione |
| 19125-99-6 |
| 2-butyl-6-(butylamino)benzo[de]isoquinoline-1,3-dione |
| AKOS003611595 |
| NCGC00246448-01 |
| 2-butyl-6-(butylamino)-1h-benzo[de]isoquinoline-1,3(2h)-dione |
| STK530702 |
| einecs 242-828-7 |
| 4-(butylamino)-n-butyl-1,8-naphthalimide |
| 4-butylamino-n-butyl-1,8-naphthalimide |
| 1h-benz(de)isoquinoline-1,3(2h)-dione, 2-butyl-6-(butylamino)- |
| CCG-46786 |
| HMS2801M18 |
| 1h-benz[de]isoquinoline-1,3(2h)-dione, 2-butyl-6-(butylamino)- |
| diethylethylidenemalonate |
| CHEMBL1472131 |
| DTXSID3051830 |
| solvent yellow 43 |
| SCHEMBL372370 |
| 2-butyl-6-(butylamino)benzo[de]isoquinoline-1,3-quinone |
| bdbm51269 |
| cid_87935 |
| 12226-96-9 |
| n-butyl-4-butylaminonaphthalimide |
| n-butyl-4-butylamino-1,8-naphthalimide |
| mfcd01165667 |
| fluorol 7ga |
| c.i.solvent yellow 43 |
| UC7 , |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 1.0000 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 10.0000 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 89.1251 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.0795 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| RGS12 | Homo sapiens (human) | Potency | 14.1254 | 0.7943 | 10.9914 | 25.1189 | AID2390 |
| WRN | Homo sapiens (human) | Potency | 89.1251 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 28.1838 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.3489 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| TDP1 protein | Homo sapiens (human) | Potency | 23.2626 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 6.7740 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| Smad3 | Homo sapiens (human) | Potency | 10.0000 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 14.1254 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| PINK1 | Homo sapiens (human) | Potency | 44.6684 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| 67.9K protein | Vaccinia virus | Potency | 20.8114 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| Parkin | Homo sapiens (human) | Potency | 44.6684 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 8.9125 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| IDH1 | Homo sapiens (human) | Potency | 18.3564 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 8.9125 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 28.1838 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
| runt-related transcription factor 1 isoform AML1b | Homo sapiens (human) | Potency | 3.9811 | 0.0200 | 7.9858 | 39.8107 | AID504374 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 79.4328 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 31.6228 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
| core-binding factor subunit beta isoform 2 | Homo sapiens (human) | Potency | 3.9811 | 0.0200 | 7.9858 | 39.8107 | AID504374 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 5.0119 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 50.1187 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 11.2202 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 6.3096 | 0.6561 | 9.4520 | 25.1189 | AID463254 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 2.1192 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 15.8489 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
| snurportin-1 | Homo sapiens (human) | Potency | 35.4813 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 11.9955 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 14.6121 | 0.1298 | 10.8331 | 32.6090 | AID493005; AID651600 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 11.2202 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| geminin | Homo sapiens (human) | Potency | 13.9520 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 10.0000 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 67.8335 | 6.3096 | 60.2008 | 112.2020 | AID720707; AID720709 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 11.2202 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 67.7407 | 3.9811 | 46.7448 | 112.2020 | AID720708; AID720711 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| metallo beta-lactamase | Pseudomonas aeruginosa | IC50 (µMol) | 25.9440 | 0.0339 | 2.9100 | 6.2480 | AID2754 |
| metallo-beta-lactamase IMP-1 | Pseudomonas aeruginosa | IC50 (µMol) | 37.1540 | 3.2410 | 5.9685 | 8.6960 | AID2756 |
| toll-like receptor 9 | Homo sapiens (human) | IC50 (µMol) | 3.5930 | 1.8690 | 5.4371 | 9.2420 | AID588340 |
| B1 bradykinin receptor | Homo sapiens (human) | IC50 (µMol) | 37.1540 | 0.0009 | 1.6209 | 3.2410 | AID2756 |
| BZLF2 | Human herpesvirus 4 type 2 (Epstein-Barr virus type 2) | IC50 (µMol) | 0.4200 | 0.4200 | 4.4342 | 16.2300 | AID1419 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 (µMol) | 3.4815 | 0.7091 | 5.0549 | 7.7510 | AID2755; AID588341 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| insulin-degrading enzyme isoform 1 | Homo sapiens (human) | EC50 (µMol) | 54.6610 | 2.0260 | 5.1785 | 8.9430 | AID588439; AID588681 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||